| Literature DB >> 31537554 |
Ailifeire Maimaiti1, Yang Li1, Yong-Tao Wang1, Xiang Yang1, Xiao-Mei Li1, Yi-Ning Yang1, Yi-Tong Ma2.
Abstract
OBJECTIVE: Insufficient myocardial reperfusion for patients with acute myocardial infarction (AMI) during primary percutaneous coronary intervention (PPCI) has a great influence on prognosis. The aim of this study was to investigate the association of the platelet-to-lymphocyte ratio (PLR) with myocardial reperfusion and in-hospital major adverse cardiac events (MACEs) in patients with AMI undergoing PPCI.Entities:
Keywords: AMI; PLR; Platelet to lymphocyte ratio; acute myocardial infarction; insufficient myocardial perfusion
Year: 2019 PMID: 31537554 PMCID: PMC6756339 DOI: 10.1136/bmjopen-2018-025628
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Baseline clinical characteristics of patients
| High PLR (n=150) | Low PLR (n=295) | P value | |
| Age, years x±s | 62.2±14.1 | 59.5±12.2 | 0.117 |
| Male, n (%) | 93 (62) | 196 (66.4) | 0.335 |
| Hypertension, n (%) | 80 (53.3) | 160 (54.2) | 0.856 |
| Diabetes, n (%) | 33 (22) | 80 (27.1) | 0.241 |
| Stroke, n (%) | 13 (8.7) | 20 (6.8) | 0.473 |
| Smoking, n (%) | 57 (38) | 130 (44.1) | 0.220 |
| Hyperlipidaemia, n (%) | 6 (4) | 16 (5.4) | 0.513 |
| Killip class ≥II, n (%) | 129 (86%) | 220 (74.6%) | 0.006 |
| Ejection fraction, x%±s | 34.8±6.0 | 37.4±7.1 | 0.006 |
| Symptom onset to intervention | 7.00±4.83 | 7.15±4.80 | 0.608 |
| ≥6 | 66 (44.0%) | 131 (44.4%) | 0.935 |
PLR, platelet-to-lymphocyte ratio.
Comparison of laboratory results
| High PLR (n=150) | Low PLR (n=295) | P value | |
| WCC×109/L (x±s) | 9.5±4.1 | 9.0±3.2 | 0.044 |
| Neutrophil ×109/L (x±s) | 8.1±6.8 | 6.5±6.2 | 0.171 |
| Platelet ×109/L (x±s) | 264.2±85.9 | 203.5±74.6 | 0.006 |
| Lymphocyte ×109/L (x±s) | 1.15±0.47 | 2.23±2.41 | 0.081 |
| Monocyte ×109/L (x±s) | 0.5±0.3 | 1.0±4.6 | 0.167 |
| Haemoglobin (g/L, x±s)) | 129.6±23.7 | 135.8±23.0 | 0.524 |
| RDW (%, x±s) | 13.6±3.1 | 13.2±2.3 | 0.026 |
| ALT (U/L, x±s) | 64.4±84.4 | 52.1±60.0 | 0.003 |
| Creatinine (μmol/L, x±s) | 76.3±30.8 | 78.4±36.3 | 0.336 |
| Total cholesterol (μmol/L, x±s) | 4.1±1.0 | 4.1±1.1 | 0.198 |
| HDL-cholesterol (µmol/L, x±s) | 1.1±0.3 | 1.0±0.5 | 0.446 |
| LDL-cholesterol (μmol/L, x±s) | 2.5±0.8 | 2.5±0.9 | 0.880 |
| CRP (mg/L, x±s) | 17.8±32.0 | 16.7±26.6 | 0.611 |
| Peak cTnT (U/L, x±s) | 5.7±4.0 | 4.9±3.8 | 0.236 |
| Peak CK-MB (U/L, x±s) | 242±382 | 226±335 | 0.498 |
| BNP (pg/mL, x±s) | 614±600 | 316±429 | <0.001 |
ALT, alanine aminotransferase; BNP, brain natriuretic peptide; CK-MB, creatine kinase-myocardial band; CRP, C-reactive protein; cTnT, cardiac troponin T; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PLR, platelet-to-lymphocyte ratio; RDW, red cell distribution width; WCC, white cell count.
Angiographic and procedural characteristics of patients
| High PLR (n=150) | Low PLR (n=295) | P value | |
| Number of diseased vessels | |||
| 1, n (%) | 54 (36) | 103 (35) | 0.821 |
| ≥2, n (%) | 96 (64) | 192 (65) | |
| Number of stent use | |||
| 1, n (%) | 66 (44) | 119 (40) | 0.459 |
| ≥2, n (%) | 84 (56) | 176 (60) | |
| Stent length, average (mm, x±s) | 26.4±8.1 | 25.9±6.3 | 0.067 |
| Stent diameter, average (mm, x±s) | 2.93±0.47 | 2.96±0.40 | 0.015 |
| Tirofiban use, n (%) | 135 (90) | 271 (92) | 0.511 |
| Thrombus aspiration, n (%) | 96 (64) | 153 (52) | 0.015 |
| Postprocedural TIMI grade | |||
| 0–2, n (%) | 25 (17) | 29 (10) | 0.037 |
| 3, n (%) | 125 (83) | 266 (90) | |
| MBG grade | |||
| 0 and 1, n (%) | 16 (11) | 12 (4) | 0.007 |
| 2 and 3, n (%) | 134 (89) | 283 (96) | |
| Insufficient myocardial reperfusion, n (%) | 35 (23) | 37 (13) | 0.003 |
MBG, myocardial blush grade; PLR, platelet-to-lymphocyte ratio; TIMI, thrombolysis in myocardial infarction.
In-hospital cardiac events and complications
| High PLR (n=150) | Low PLR (n=295) | P value | |
| MACEs, n (%) | 64 (43) | 95 (32) | 0.029 |
| Non-lethal myocardial infarction, n (%) | 6 (4) | 7 (2) | 0.335 |
| Stroke, n (%) | 11 (7) | 18 (6) | 0.619 |
| In-hospital mortality, n (%) | 4 (3) | 2 (1) | 0.186 |
| Ventricular tachycardia/ventricular fibrillation, n (%) | 42 (28) | 69 (23) | 0.288 |
MACEs, major adverse cardiac events (cardiovascular death, reinfarction and target vessel revascularisation); PLR, platelet-to-lymphocyte ratio.
The independent predictors of insufficient myocardial reperfusion
| Variable | Univariate | Multivariate | ||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | 1.013 (0.983 to 1.033) | 0.202 | 1.008 (0.988 to 1.028) | 0.440 |
| Male sex | 1.018 (0.599 to 1.728) | 0.948 | 1.009 (0.554 to 1.839) | 0.975 |
| Killip class ≥II | 1.167 (0.620 to 2.198) | 0.632 | 0.980 (0.460 to 2.086) | 0.958 |
| Ejection fraction | 0.985 (0.948 to 1.023) | 0.436 | 0.986 (0.947 to 1.027) | 0.488 |
| WCC | 1.049 (0.983 to 1.119) | 0.151 | 1.044 (0.977 to 1.116) | 0.206 |
| Platelet | 1.002 (0.999 to 1.005) | 0.037 | 1.000 (0.996 to 1.005) | 0.872 |
| Lymphocyte | 0.766 (0.542 to 1.082) | 0.130 | 0.906 (0.611 to 1.344) | 0.624 |
| RDW | 1.016 (0.928 to 1.112) | 0.734 | 1.008 (0.911 to 1.115) | 0.878 |
| ALT | 0.999 (0.995 to 1.003) | 0.576 | 0.991 (0.993 to 1.002) | 0.268 |
| Stent length | 1.007 (0.971 to 1.044) | 0.710 | 1.005 (0.969 to 1.042) | 0.793 |
| Stent diameter | 1.168 (0.643 to 2.124) | 0.610 | 1.071 (0.571 to 2.009) | 0.831 |
| Thrombus aspiration | 1.123 (0.673 to 1.872) | 0.657 | 1.046 (0.614 to 1.780) | 0.869 |
| BNP | 1.329 (1.057 to 1.672) | 0.015 | 1.328 (1.056 to 1.670) | 0.015 |
| PLR | 1.254 (1.001 to 1.571) | 0.051 | 1.256 (1.003 to 1.579) | 0.056 |
ALT, alanine aminotransferase; BNP, brain natriuretic peptide; PLR, platelet-to-lymphocyte ratio; RDW, red cell distribution width; WCC, white cell count.